NCT06926790View on ClinicalTrials.gov

Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)

PHASE2RecruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

March 31, 2030

Study Completion Date

October 31, 2030

Conditions
Lung Cancer - Non Small Cell
Interventions
DRUG

Nivolumab & Ipilimumab

This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.

Trial Locations (1)

510120

RECRUITING

First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER